566 related articles for article (PubMed ID: 26986571)
1. Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines.
Kim J; Lee J; Jang SY; Kim C; Choi Y; Kim A
Oncol Rep; 2016 May; 35(5):2553-60. PubMed ID: 26986571
[TBL] [Abstract][Full Text] [Related]
2. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.
Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA
IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736
[TBL] [Abstract][Full Text] [Related]
3. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
Kim J; Lee J; Kim C; Choi J; Kim A
Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
[TBL] [Abstract][Full Text] [Related]
4. Leptin attenuates the anti-estrogen effect of tamoxifen in breast cancer.
Chen X; Zha X; Chen W; Zhu T; Qiu J; Røe OD; Li J; Wang Z; Yin Y
Biomed Pharmacother; 2013 Feb; 67(1):22-30. PubMed ID: 23199901
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M
Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749
[TBL] [Abstract][Full Text] [Related]
6. Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifen-resistant breast cancer cells.
Riggs KA; Wickramasinghe NS; Cochrum RK; Watts MB; Klinge CM
Cancer Res; 2006 Oct; 66(20):10188-98. PubMed ID: 17047084
[TBL] [Abstract][Full Text] [Related]
7. Activation of the MKL1/actin signaling pathway induces hormonal escape in estrogen-responsive breast cancer cell lines.
Kerdivel G; Boudot A; Habauzit D; Percevault F; Demay F; Pakdel F; Flouriot G
Mol Cell Endocrinol; 2014 Jun; 390(1-2):34-44. PubMed ID: 24721635
[TBL] [Abstract][Full Text] [Related]
8. Ethoxy mansonone G as an anticancer agent in estrogen receptor-positive and endocrine-resistant breast cancer.
Chonsut P; Mahalapbutr P; Pradubyat N; Chavasiri W; Wonganan P; Ketchart W
J Pharm Pharmacol; 2019 Dec; 71(12):1839-1853. PubMed ID: 31588558
[TBL] [Abstract][Full Text] [Related]
9. Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ERα-negative Breast Cancers to Tamoxifen through ERα Reexpression.
Anbalagan M; Sheng M; Fleischer B; Zhang Y; Gao Y; Hoang V; Matossian M; Burks HE; Burow ME; Collins-Burow BM; Hangauer D; Rowan BG
Mol Cancer Res; 2017 Nov; 15(11):1491-1502. PubMed ID: 28751463
[TBL] [Abstract][Full Text] [Related]
10. Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.
Barone I; Brusco L; Gu G; Selever J; Beyer A; Covington KR; Tsimelzon A; Wang T; Hilsenbeck SG; Chamness GC; Andò S; Fuqua SA
J Natl Cancer Inst; 2011 Apr; 103(7):538-52. PubMed ID: 21447808
[TBL] [Abstract][Full Text] [Related]
11. Harmful effect of ERβ on BCRP-mediated drug resistance and cell proliferation in ERα/PR-negative breast cancer.
Li W; Jia M; Qin X; Hu J; Zhang X; Zhou G
FEBS J; 2013 Dec; 280(23):6128-40. PubMed ID: 24103091
[TBL] [Abstract][Full Text] [Related]
12. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
[TBL] [Abstract][Full Text] [Related]
13. Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ.
Mishra AK; Abrahamsson A; Dabrosin C
Oncotarget; 2016 Aug; 7(35):56876-56888. PubMed ID: 27486755
[TBL] [Abstract][Full Text] [Related]
14. Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells.
Fox EM; Bernaciak TM; Wen J; Weaver AM; Shupnik MA; Silva CM
Mol Endocrinol; 2008 Aug; 22(8):1781-96. PubMed ID: 18550772
[TBL] [Abstract][Full Text] [Related]
15. Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer.
Osipo C; Meeke K; Cheng D; Weichel A; Bertucci A; Liu H; Jordan VC
Int J Oncol; 2007 Feb; 30(2):509-20. PubMed ID: 17203234
[TBL] [Abstract][Full Text] [Related]
16. Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells.
Berstein LM; Yue W; Wang JP; Santen RJ
Breast Cancer Res Treat; 2011 Jul; 128(1):109-17. PubMed ID: 20683653
[TBL] [Abstract][Full Text] [Related]
17. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
[TBL] [Abstract][Full Text] [Related]
18. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer.
Li Y; Meeran SM; Patel SN; Chen H; Hardy TM; Tollefsbol TO
Mol Cancer; 2013 Feb; 12():9. PubMed ID: 23379261
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines.
Alao JP; Lam EW; Ali S; Buluwela L; Bordogna W; Lockey P; Varshochi R; Stavropoulou AV; Coombes RC; Vigushin DM
Clin Cancer Res; 2004 Dec; 10(23):8094-104. PubMed ID: 15585645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
